AngioDynamics (US.ANGO)

资本配置审计 · 期间: 20102026

$打开交互终端运行 `audit` 并探索所有维度。

核心指标

US.ANGO · 同比: 2026 ANNUAL vs 2025 ANNUAL

指标数值同比
FCF Conversion16.4%
ROE-21.5%
Cash Conversion-
D/E Ratio0.00
Gross Margin54.6%
US.ANGO (AngioDynamics) | YoY: 2026 ANNUAL vs 2025 ANNUAL


Metric            Value  YoY
----------------------------
FCF Conversion    16.4%    ↓
ROE              -21.5%    ↓
Cash Conversion       -    →
D/E Ratio          0.00    ↓
Gross Margin      54.6%    →
核心指标
US.ANGO (AngioDynamics) | YoY: 2026 ANNUAL vs 2025 ANNUAL
Metric Value YoY
----------------------------
FCF Conversion 16.4%
ROE -21.5%
Cash Conversion -
D/E Ratio 0.00
Gross Margin 54.6%

审计维度

免费公司